胰高血糖素样肽-1 (GLP-1)受体激动剂在酒精相关行为中的作用的系统综述:酒精使用障碍的潜在治疗策略

IF 2.6 4区 医学 Q3 NEUROSCIENCES
Yang Jing Zheng, Crystaleene Soegiharto, Hezekiah C T Au, Kyle Valentino, Gia Han Le, Sabrina Wong, Kayla M Teopiz, Taeho Greg Rhee, Hernan F Guillen-Burgos, Bing Cao, Roger S McIntyre
{"title":"胰高血糖素样肽-1 (GLP-1)受体激动剂在酒精相关行为中的作用的系统综述:酒精使用障碍的潜在治疗策略","authors":"Yang Jing Zheng, Crystaleene Soegiharto, Hezekiah C T Au, Kyle Valentino, Gia Han Le, Sabrina Wong, Kayla M Teopiz, Taeho Greg Rhee, Hernan F Guillen-Burgos, Bing Cao, Roger S McIntyre","doi":"10.1017/neu.2025.6","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Extant literature implicates the role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) on modulating alcohol-associated behaviours, with a particular emphasis of these agents on neural circuits subserving reward and appetite control. Herein, we explore the potential effects of GLP-1RAs on alcohol-associated behaviours in brain regions implicated in reward processing facilitating the repurposing of these agents for the treatment and prevention of problematic drinking. Understanding how GLP-1's analogues interact with alcohol-related behaviours may underscore the development of therapeutic strategies for alcohol use disorder (AUD) and those with comorbid metabolic disorders.</p><p><strong>Methods: </strong>A systematic review was conducted, wherein relevant literature was identified through Web of Science, PubMed, and OVID (MedLINE, Embase, AMED, PsycInfo, JBI EBP) from database inception to October 27th, 2024. Preclinical and clinical studies examining the association between GLP-1RAs and alcohol-related behaviours were assessed.</p><p><strong>Results: </strong>Preclinical studies (<i>n</i> = 19) indicate that GLP-1RAs attenuate alcohol-related behaviours, with exenatide demonstrating significant dose-dependent effects in high alcohol-consuming phenotypes. Semaglutide and liraglutide are associated with reduced alcohol intake, though their effects were often transient. In human studies (<i>n</i> = 2) with AUD, semaglutide significantly reduced alcohol consumption, while exenatide showed mixed results, with reductions in alcohol drinking within high BMI subpopulations.</p><p><strong>Discussion: </strong>Extant preclinical and clinical literature provides preliminary support for the potential therapeutic role of GLP-1RAs in attenuating alcohol consumption and preference. There is a need for large well controlled studies evaluating the effect of GLP-1RAs as a treatment strategy for behavioural modifications in individuals living with alcohol use disorder.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"e51"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.\",\"authors\":\"Yang Jing Zheng, Crystaleene Soegiharto, Hezekiah C T Au, Kyle Valentino, Gia Han Le, Sabrina Wong, Kayla M Teopiz, Taeho Greg Rhee, Hernan F Guillen-Burgos, Bing Cao, Roger S McIntyre\",\"doi\":\"10.1017/neu.2025.6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Extant literature implicates the role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) on modulating alcohol-associated behaviours, with a particular emphasis of these agents on neural circuits subserving reward and appetite control. Herein, we explore the potential effects of GLP-1RAs on alcohol-associated behaviours in brain regions implicated in reward processing facilitating the repurposing of these agents for the treatment and prevention of problematic drinking. Understanding how GLP-1's analogues interact with alcohol-related behaviours may underscore the development of therapeutic strategies for alcohol use disorder (AUD) and those with comorbid metabolic disorders.</p><p><strong>Methods: </strong>A systematic review was conducted, wherein relevant literature was identified through Web of Science, PubMed, and OVID (MedLINE, Embase, AMED, PsycInfo, JBI EBP) from database inception to October 27th, 2024. Preclinical and clinical studies examining the association between GLP-1RAs and alcohol-related behaviours were assessed.</p><p><strong>Results: </strong>Preclinical studies (<i>n</i> = 19) indicate that GLP-1RAs attenuate alcohol-related behaviours, with exenatide demonstrating significant dose-dependent effects in high alcohol-consuming phenotypes. Semaglutide and liraglutide are associated with reduced alcohol intake, though their effects were often transient. In human studies (<i>n</i> = 2) with AUD, semaglutide significantly reduced alcohol consumption, while exenatide showed mixed results, with reductions in alcohol drinking within high BMI subpopulations.</p><p><strong>Discussion: </strong>Extant preclinical and clinical literature provides preliminary support for the potential therapeutic role of GLP-1RAs in attenuating alcohol consumption and preference. There is a need for large well controlled studies evaluating the effect of GLP-1RAs as a treatment strategy for behavioural modifications in individuals living with alcohol use disorder.</p>\",\"PeriodicalId\":48964,\"journal\":{\"name\":\"Acta Neuropsychiatrica\",\"volume\":\" \",\"pages\":\"e51\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-02-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Neuropsychiatrica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/neu.2025.6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neuropsychiatrica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/neu.2025.6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

现有文献暗示胰高血糖素样肽-1 (GLP-1)和GLP-1受体激动剂(GLP-1RAs)在调节酒精相关行为中的作用,并特别强调这些药物在神经回路中提供奖励和食欲控制。在此,我们探讨了GLP-1RAs在涉及奖励处理的大脑区域中对酒精相关行为的潜在影响,促进了这些药物在治疗和预防问题饮酒中的再利用。了解GLP-1类似物如何与酒精相关行为相互作用,可能会强调酒精使用障碍(AUD)和伴随代谢障碍的治疗策略的发展。方法:系统检索Web of Science、PubMed、OVID (MedLINE、Embase、AMED、PsycInfo、JBI EBP)数据库自建库至2024年10月27日的相关文献。评估了GLP-1RAs与酒精相关行为之间关系的临床前和临床研究。结果:临床前研究(n = 19)表明,GLP-1RAs可减弱酒精相关行为,艾塞那肽在高酒精消耗表型中表现出显著的剂量依赖效应。西马鲁肽和利拉鲁肽与减少酒精摄入量有关,尽管它们的作用通常是短暂的。在患有AUD的人类研究中(n = 2),西马鲁肽显著减少了酒精摄入量,而艾塞那肽显示出混合结果,在高BMI亚群中减少了酒精摄入量。讨论:现有的临床前和临床文献为GLP-1RAs在减少酒精消耗和偏好方面的潜在治疗作用提供了初步支持。有必要进行大型对照研究,评估GLP-1RAs作为酒精使用障碍患者行为改变的治疗策略的效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.

Introduction: Extant literature implicates the role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) on modulating alcohol-associated behaviours, with a particular emphasis of these agents on neural circuits subserving reward and appetite control. Herein, we explore the potential effects of GLP-1RAs on alcohol-associated behaviours in brain regions implicated in reward processing facilitating the repurposing of these agents for the treatment and prevention of problematic drinking. Understanding how GLP-1's analogues interact with alcohol-related behaviours may underscore the development of therapeutic strategies for alcohol use disorder (AUD) and those with comorbid metabolic disorders.

Methods: A systematic review was conducted, wherein relevant literature was identified through Web of Science, PubMed, and OVID (MedLINE, Embase, AMED, PsycInfo, JBI EBP) from database inception to October 27th, 2024. Preclinical and clinical studies examining the association between GLP-1RAs and alcohol-related behaviours were assessed.

Results: Preclinical studies (n = 19) indicate that GLP-1RAs attenuate alcohol-related behaviours, with exenatide demonstrating significant dose-dependent effects in high alcohol-consuming phenotypes. Semaglutide and liraglutide are associated with reduced alcohol intake, though their effects were often transient. In human studies (n = 2) with AUD, semaglutide significantly reduced alcohol consumption, while exenatide showed mixed results, with reductions in alcohol drinking within high BMI subpopulations.

Discussion: Extant preclinical and clinical literature provides preliminary support for the potential therapeutic role of GLP-1RAs in attenuating alcohol consumption and preference. There is a need for large well controlled studies evaluating the effect of GLP-1RAs as a treatment strategy for behavioural modifications in individuals living with alcohol use disorder.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Neuropsychiatrica
Acta Neuropsychiatrica NEUROSCIENCES-PSYCHIATRY
自引率
5.30%
发文量
30
期刊介绍: Acta Neuropsychiatrica is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The Journal''s scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信